Egan-Jones Recommends Against Electing Dissident's Full Slate of Nominees to Ziopharm Board Nasdaq:ZIOP
s Independent financial analysts widely recognize this progress: “ZIOP continues to make progress with respect to the company-sponsored TCR-T program, the Controlled IL-12 program, and the Sleeping Beauty CAR-T program.” 2 “By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy.” 3 “We think that the company continues to make forward progress across its various platforms (TCR-T, CAR-T, and controlled IL-12)...ZIOP has executed well over 2020 in curating immune receptors from its own libra...